期刊
BIOMARKERS
卷 17, 期 8, 页码 706-713出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/1354750X.2012.719037
关键词
Acute heart failure; renal disease; risk stratification
资金
- Abbott Laboratories
- National Institute of Health [HL076684]
- National Heart, Lung and Blood Institute [K23HL085387]
- NIH/NCRR [1UL1RR026314-01]
Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据